ReviewJournal of clinical medicine2026

Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine.

Piotr Kawczak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.